University Hospital, 339 Windermere Rd., London, Ontario
Dr. Marotta is the Medical Director of Liver Transplantation at the London Health Sciences Centre in London, Ontario and is the Co-Program Director of the Advanced Hepatology/Liver Transplantation Fellowship Program. Dr. Marotta is a past president of the Canadian Liver Transplant Network and the Governing Board of the CASL. He is a provincial lead in policy for liver transplant allocation in Ontario and a member of several national and international organizations including the AASLD and the International Liver Transplant Society. He is on several editorial boards of many high impact journals with over seventy peer reviewed publications in various areas including viral hepatitis, hepatitis B and hepatitis C, autoimmune liver disease, liver transplantation, and immunosuppressive therapy.
Management of Hepatitis B : A Longitudinal national survey-impact of the Canadian Hepatitis B Consensus Guidelines. Marotta P, Lucas, K. Can J Gastroenterol. 2010 Sept;24(4):537-42.
Clinical outcomes of liver transplantation for polycystic liver disease: a single center experience. Chandok N, Uhanova J, Marotta P.Ann Hepatol. 2010 Jul 1;9(3):278-81
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, Gordon SC, Marotta P, Vierling JM, Lopez-Talavera JC, Byrnes-Blake K, Fontana D, Freeman J, Gray T, Hausman D, Hunder NN, Lawitz E. Hepatology. 2010 Sep;52(3):822-32.
Identifying HCV genotype 1 patients at risk of relapse. Deschenes M; Bain VG; Lee SS; Sherman M; Cooper CL; Yoshida EM; Marotta PJ; Krajden M; Usaty C; Balshaw R; Peltekian KM; Canadian Pegasys Study Group. European Journal of Gastroenterology & Hepatology. 22(5):546-51, 2010 May.